AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation rates by 29% and 34% among former smokers. Its OBERON and TITANIA trials were replicate, double-blind, placebo-controlled studies involving a total of 2,306 patients with symptomatic COPD and a history of at least two moderate […]
The post AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials appeared first on Pharmafile.